JP2025512818A - 可溶化したブラジキニンｂ２受容体アンタゴニストを含む固体組成物 - Google Patents

可溶化したブラジキニンｂ２受容体アンタゴニストを含む固体組成物 Download PDF

Info

Publication number
JP2025512818A
JP2025512818A JP2024556786A JP2024556786A JP2025512818A JP 2025512818 A JP2025512818 A JP 2025512818A JP 2024556786 A JP2024556786 A JP 2024556786A JP 2024556786 A JP2024556786 A JP 2024556786A JP 2025512818 A JP2025512818 A JP 2025512818A
Authority
JP
Japan
Prior art keywords
disorders
solid dispersion
weight
sustained release
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512818A5 (enExample
Inventor
ギブソン，クリストフ
Original Assignee
ファルバリス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルバリス ゲーエムベーハー filed Critical ファルバリス ゲーエムベーハー
Publication of JP2025512818A publication Critical patent/JP2025512818A/ja
Publication of JP2025512818A5 publication Critical patent/JP2025512818A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024556786A 2022-03-25 2023-03-27 可溶化したブラジキニンｂ２受容体アンタゴニストを含む固体組成物 Pending JP2025512818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164462.8 2022-03-25
EP22164462 2022-03-25
PCT/EP2023/057791 WO2023180575A1 (en) 2022-03-25 2023-03-27 Solid composition comprising solubilised bradykinin b2-receptor antagonists

Publications (2)

Publication Number Publication Date
JP2025512818A true JP2025512818A (ja) 2025-04-22
JP2025512818A5 JP2025512818A5 (enExample) 2026-04-06

Family

ID=80952146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556786A Pending JP2025512818A (ja) 2022-03-25 2023-03-27 可溶化したブラジキニンｂ２受容体アンタゴニストを含む固体組成物

Country Status (16)

Country Link
US (1) US20250228781A1 (enExample)
EP (1) EP4499038B1 (enExample)
JP (1) JP2025512818A (enExample)
KR (1) KR20240161689A (enExample)
CN (1) CN119136785A (enExample)
AU (1) AU2023241243A1 (enExample)
CA (1) CA3250835A1 (enExample)
CO (1) CO2024012879A2 (enExample)
ES (1) ES3062067T3 (enExample)
HR (1) HRP20260166T1 (enExample)
IL (1) IL315699A (enExample)
MA (1) MA69209B1 (enExample)
MX (1) MX2024011703A (enExample)
PL (1) PL4499038T3 (enExample)
WO (1) WO2023180575A1 (enExample)
ZA (1) ZA202408058B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102824038B1 (ko) 2025-01-20 2025-06-23 송재혁 차량 종합 검사 시스템

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168667A (zh) 1994-10-27 1997-12-24 藤沢药品工业株式会社 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1085895A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Bradykinin antagonists
EP1123288A1 (en) 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
JP2005525398A (ja) 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
CA3198246A1 (en) * 2020-11-12 2022-05-19 Pharvaris Gmbh Prophylaxis and treatment of angioedema

Also Published As

Publication number Publication date
EP4499038A1 (en) 2025-02-05
PL4499038T3 (pl) 2026-04-27
IL315699A (en) 2024-11-01
EP4499038B1 (en) 2025-12-03
CN119136785A (zh) 2024-12-13
MX2024011703A (es) 2024-11-08
AU2023241243A1 (en) 2024-11-07
CA3250835A1 (en) 2023-09-28
KR20240161689A (ko) 2024-11-12
ZA202408058B (en) 2026-01-28
EP4499038C0 (en) 2025-12-03
HRP20260166T1 (hr) 2026-03-27
WO2023180575A1 (en) 2023-09-28
US20250228781A1 (en) 2025-07-17
MA69209B1 (fr) 2026-03-31
ES3062067T3 (en) 2026-04-08
CO2024012879A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
US12629369B2 (en) Pharmaceutical compositions of nilotinib
JP5017115B2 (ja) ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物
US12357627B2 (en) Pharmaceutical compositions of cabozantinib
JP2010519201A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
AU2008309385A1 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
EP4499038B1 (en) Solid composition comprising solubilised bradykinin b2-receptor antagonists
CA3200729A1 (en) Pharmaceutical composition comprising meloxicam
EP4499039B1 (en) Solid extended-release composition comprising bradykinin b2-receptor antagonists
US20250268887A1 (en) Therapeutic uses of bradykinin b2-receptor antagonists
EA052832B1 (ru) Твердая композиция с пролонгированным высвобождением, содержащая антагонисты брадикининовых в2-рецепторов
CN105726499B (zh) 一种利伐沙班药物组合物及其制备方法
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
CA3300190A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
CN120076794A (zh) 包含纳波拉非尼的无定形固体分散体
TW202404580A (zh) 複數個顆粒
US20210275546A1 (en) High drug load solid oral dosage forms of dexamethasone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260326